Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 7/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098282 | 0.86 | P2RY6 (0.38) | SLC6A11SLC6A1TYMP | |
| SCHEMBL4074748 | 0.86 | P2RY6 (0.38) | SLC6A11SLC6A1TYMP | |
| SCHEMBL2769235 | 0.83 | TK2 (0.42) | — | |
| SCHEMBL5582060 | 0.83 | TK2 (0.42) | — | |
| SCHEMBL5557408 | 0.83 | TK2 (0.42) | — | |
| SCHEMBL24512779 | 0.83 | TK2 (0.42) | — | |
| SCHEMBL31556076 | 0.83 | TYMP (0.39) | SLC6A11SLC6A1TYMPNPY2RSLC6A12 | |
| SCHEMBL5992442 | 0.82 | P2RY6 (0.43) | SLC6A11SLC6A1TYMP | |
| SCHEMBL4082385 | 0.82 | P2RY6 (0.43) | SLC6A11SLC6A1TYMP | |
| SCHEMBL1096600 | 0.82 | P2RY6 (0.43) | SLC6A11SLC6A1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053199-B2 | Nucleoside analogs and oligonucleotide derivatives containing these analogs | Imanishi, Takeshi (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040192918-A1 | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs | IMANISHI, TAKESHI (JP) | 2004-09-30 | — | — | US | disclosed |
| EP-1314734-A1 | NOVEL NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING THESE ANALOGS | Imanishi, Takeshi (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192918-A1 | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs | DCLRE1B, POLB, POLR1E | SLC6A11 4785/4885SLC6A1 4740/4885TYMP 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.